CN110042101A - Reduce siRNA, recombinant vector and its application of ROGDI gene expression - Google Patents
Reduce siRNA, recombinant vector and its application of ROGDI gene expression Download PDFInfo
- Publication number
- CN110042101A CN110042101A CN201910203977.6A CN201910203977A CN110042101A CN 110042101 A CN110042101 A CN 110042101A CN 201910203977 A CN201910203977 A CN 201910203977A CN 110042101 A CN110042101 A CN 110042101A
- Authority
- CN
- China
- Prior art keywords
- seq
- nucleotide sequence
- group
- shrna
- sirna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to molecular biology and gene engineering technology field, are related to a kind of siRNA, recombinant vector and its application for reducing ROGDI gene expression.In particular it relates to a kind of siRNA, the siRNA specifically reduces ROGDI gene expression.Since siRNA provided by the invention can specifically reduce ROGDI gene expression, so that the siRNA can be applied to the drug of preparation treatment and/or prevention breast cancer.
Description
Technical field
The invention belongs to molecular biology and gene engineering technology field, more particularly, to a kind of reduction ROGDI gene
The siRNA of expression, the corresponding shRNA of the siRNA, encode the DNA of the shRNA, the recombinant vector including the DNA, including
The recombinant slow virus of the recombinant vector, including the siRNA, shRNA, the DNA for encoding shRNA, recombinant vector and recombinant lentiviral disease
The host cell of poison and their application.
Background technique
Breast cancer is one of the malignant tumour that women is common in world wide, and new hair rate and the death rate occupy all kinds of cancers
It is the first.Although China's breast cancer incidence is relatively low, large population base, overall incidence number is more, and disease incidence has on year by year
The trend risen, and age of onset is in rejuvenation trend.Breast cancer is in origin of cell, Histological Study, disease classification, clinical table
Existing, therapeutic response and metastatic potential etc. all show great complexity and heterogeneity, limit existing breast cancer and control
The validity and popularity for the treatment of method.Clinically still lack the target spot of breast cancer treatment.
ROGDI (Rogdi atypical leucine zipper, ROGDI) also known as KTZS.The gene of the encoding histone
It is positioned at 16p13.3, there is 11 exons, the great expression usually in the histoorgans such as the brain of the mankind, marrow, heart.It is logical
Cross further study show that, which is positioned in nucleus, cytoplasm and mitochondria.However, up to the present, to ROGDI
Biological function have not been reported.
Summary of the invention
The object of the present invention is to provide a kind of siRNA, recombinant vector and its applications for reducing ROGDI gene expression, with spy
ROGDI gene expression is reduced, anisotropicly so as to treat and/or prevent breast cancer.
To achieve the goals above, the first aspect of the present invention provides a kind of siRNA, and the siRNA is specifically reduced
ROGDI gene expression.
Of the invention focuses on providing new breast cancer treatment target, and is not limited to specific siRNA sequence, Ke Yigen
The siRNA of the target is directed to according to the various methods design of this field routine.The siRNA usually has the nucleotide of 19~27bp
Sequence.
Specifically, the nucleotide sequence of the siRNA includes at least following set of nucleotide sequence:
(1) first group of nucleotide sequence
As shown in SEQ ID NO:1 and SEQ ID NO:2, the SEQ ID NO:1 is first group of nucleotide sequence
5'-GCUGGUCAACGUCUACAUCAA-3', the SEQ ID NO:2 are 5'-UUGAUGUAGACGUUGACCAGC-3'；
(2) second groups of nucleotide sequences
As shown in SEQ ID NO:3 and SEQ ID NO:4, the SEQ ID NO:3 is second group of nucleotide sequence
5'-CCAUGUGAGCCAAGCCAUUUA-3', the SEQ ID NO:4 are 5'-UAAAUGGCUUGGCUCACAUGG-3'；
(3) third group nucleotide sequence
As shown in SEQ ID NO:5 and SEQ ID NO:6, the SEQ ID NO:5 is the third group nucleotide sequence
5'-CCCACCUAACACAUUUGCACU-3', the SEQ ID NO:6 are 5'-AGUGCAAAUGUGUUAGGUGGG-3'.
The second aspect of the present invention provides a kind of shRNA, is the single stranded RNA with loop-stem structure, the core of the shRNA
Nucleotide sequence includes at least following set of nucleotide sequence:
(1) the 5th group of nucleotide sequence
As shown in SEQ ID NO:9 and SEQ ID NO:10, the SEQ ID NO:9 is the 5th group of nucleotide sequence
5'-CCGGGCUGGUCAACGUCUACAUCAACUCGAGUUGAUGUAGACGUUGACCAGCU UUUUG-3', the SEQ ID
NO:10 is 5'-AAUUCAAAAAGCUGGUCAACGUCUACAUCAACUCGAGUUGAUGUAGACGUUGA CCAGC-3'；
(2) the 6th groups of nucleotide sequences
The 6th group of nucleotide sequence is as shown in SEQ ID NO:11 and SEQ ID NO:12, the SEQ ID NO:11
For 5'-CCGGCCAUGUGAGCCAAGCCAUUUACUCGAGUAAAUGGCUUGGCUCACAUGGU UUUUG-3', the SEQ ID
NO:12 is 5'-AAUUCAAAAACCAUGUGAGCCAAGCCAUUUACUCGAGUAAAUGGCUUGGCUCA CAUGG-3'；
(3) the 7th groups of nucleotide sequences
The 7th group of nucleotide sequence is as shown in SEQ ID NO:13 and SEQ ID NO:14, the SEQ ID NO:13
For 5'-CCGGCCCACCUAACACAUUUGCACUCUCGAGAGUGCAAAUGUGUUAGGUGGGU UUUUG-3', the SEQ ID
NO:14 is 5'-AAUUCAAAAACCCACCUAACACAUUUGCACUCUCGAGAGUGCAAAUGUGUUAG GUGGG-3'.
The third aspect of the present invention provides the DNA, the DNA of a kind of shRNA that coding the second aspect of the present invention provides
Nucleotide sequence include at least following set of nucleotide sequence:
(1) the 9th group of nucleotide sequence
The 9th group of nucleotide sequence is as shown in SEQ ID NO:17 and SEQ ID NO:18, the SEQ ID NO:17
For 5'-CCGGGCTGGTCAACGTCTACATCAACTCGAGTTGATGTAGACGTTGACCAGCT TTTTG-3', the SEQ ID
NO:18 is 5'-AATTCAAAAAGCTGGTCAACGTCTACATCAACTCGAGTTGATGTAGACGTTGA CCAGC-3'；
(2) the tenth groups of nucleotide sequences
Described ten group of nucleotide sequence is as shown in SEQ ID NO:19 and SEQ ID NO:20, the SEQ ID NO:19
For 5'-CCGGCCATGTGAGCCAAGCCATTTACTCGAGTAAATGGCTTGGCTCACATGGT TTTTG-3', the SEQ ID
NO:20 is 5'-AATTCAAAAACCATGTGAGCCAAGCCATTTACTCGAGTAAATGGCTTGGCTCA CATGG-3'；
(3) the 11st groups of nucleotide sequences
The 11st group of nucleotide sequence is as shown in SEQ ID NO:21 and SEQ ID NO:22, the SEQ ID NO:
21 be 5'-CCGGCCCACCTAACACATTTGCACTCTCGAGAGTGCAAATGTGTTAGGTGGGT TTTTG-3', the SEQ
ID NO:22 is 5'-AATTCAAAAACCCACCTAACACATTTGCACTCTCGAGAGTGCAAATGTGTTAG GTGGG-3'.
The fourth aspect of the present invention provides a kind of recombinant vector, and the recombinant vector is (to be purchased from Shanghai in GV493 plasmid
Ji Kai Gene Tech. Company Limited) multiple cloning sites AgeI and EcoRI insertion as coding third aspect present invention provide volume
The recombinant vector that the DNA of code shRNA is obtained.
The fifth aspect of the present invention provides a kind of recombinant slow virus, and the recombinant slow virus is mentioned by the fourth aspect of the present invention
The recombinant vector and virus packaging 1.0 carrier of helper plasmid pHelper and virus packaging helper plasmid pHelper 2.0 of confession carry
Body cotransfection mammalian cell obtains.
The sixth aspect of the present invention provides a kind of host cell, siRNA, this hair provided including the first aspect of the present invention
The DNA of the coding shRNA of shRNA, the third aspect of the present invention offer that bright second aspect provides, the fourth aspect of the present invention
At least one of the recombinant slow virus that the recombinant vector and the fifth aspect of the present invention of offer provide.The present invention is to the host
The specific type of cell is not particularly limited, for example, 293T cell.
The seventh aspect of the present invention provides the siRNA of the first aspect of the present invention offer, the second aspect of the present invention provides
ShRNA, the recombinant vector that provides of the coding DNA of shRNA that provides of the third aspect of the present invention, the fourth aspect of the present invention and
At least one of recombinant slow virus that the fifth aspect of the present invention provides is in the preparation that preparation inhibits ROGDI gene expression
Using.
The eighth aspect of the present invention provides the siRNA of the first aspect of the present invention offer, the second aspect of the present invention provides
ShRNA, the recombinant vector that provides of the coding DNA of shRNA that provides of the third aspect of the present invention, the fourth aspect of the present invention and
At least one of recombinant slow virus that the fifth aspect of the present invention provides inhibits breast cancer cell growth and/or proliferation in preparation
Drug in application.
The ninth aspect of the present invention provides the siRNA of the first aspect of the present invention offer, the second aspect of the present invention provides
ShRNA, the recombinant vector that provides of the coding DNA of shRNA that provides of the third aspect of the present invention, the fourth aspect of the present invention and
At least one of recombinant slow virus that the fifth aspect of the present invention provides is in the drug of preparation treatment and/or prevention breast cancer
Application.
SiRNA provided by the invention can specifically reduce ROGDI gene expression, so that the siRNA can be applied to make
The standby drug treated and/or prevent breast cancer.
Other features and advantages of the present invention will then part of the detailed description can be specified.
Detailed description of the invention
Exemplary embodiment of the invention is described in more detail in conjunction with the accompanying drawings, it is of the invention above-mentioned and its
Its purpose, feature and advantage will be apparent.
Fig. 1 shows differential expression of the ROGDI in normal cell and breast cancer cell.Wherein, MCF-10A (is abbreviated as
It 10A) is normal cell, MCF7, MDA-MB-231 (being abbreviated as 231), BT-474 and SK-BR-3 are breast cancer cell.
Fig. 2 shows strike influence of the low ROGDI to Cells Proliferation of Human Breast Cancer.Wherein, shCtrl is control group, shROGDI
For experimental group, the curve of top is control group, and the curve of lower section is experimental group.
Fig. 3 shows the influence for striking low ROGDI to tumor-bearing mice growth of breast cancers.Wherein, NC is control group, shROGDI
For experimental group.
Specific embodiment
The preferred embodiment of the present invention is described in more detail below.Although the following describe preferred implementations of the invention
Mode, however, it is to be appreciated that may be realized in various forms the present invention without that should be limited by the embodiments set forth herein.It is real
The person that is not specified actual conditions in example is applied, is all carried out according to conventional conditions or manufacturer's recommended conditions.Agents useful for same or instrument are not
Production firm person is indicated, is the conventional products that can be obtained by commercially available purchase.
The number of source of people ROGDI involved in following embodiments is Gene ID:79641.
In following embodiments, statistical analysis is carried out using 6.0 software of GraphPad Prism.All experiment in vitro counterpoises
Again more than three times.Data are indicated with means standard deviation (SD).P < 0.05 is considered to have statistical significance.
Embodiment 1
The present embodiment is for illustrating that ROGDI high is expressed in breast cancer cell line.
The extraction of RNA and reverse transcription quantitative PCR (RT-qPCR).
1, Total RNAs extraction: the present embodiment carries out at low temperature.Cell culture carries out in 6 orifice plates, removes culture medium, PBS
1000 μ l of Trizol, shaking table 10min is added in rinsing 3 times, every hole；It is collected into 1.5ml centrifuge tube, 200 μ l chlorine are added in every pipe
It is imitative, 30sec is acutely mixed, 15min is stood, 4 DEG C of 12000rpm are centrifuged 15min；400 μ l of gentle aspiration supernatant liquid is to another new
In centrifuge tube, isometric isopropanol is added, is gently mixed by inversion, 4 DEG C of 12000rpm are centrifuged 10min；Supernatant is abandoned, 1ml is added
75% ethanol wash sediment, 4 DEG C of 12000rpm are centrifuged 10min；Supernatant is discarded as far as possible, dries 10min, every pipe at room temperature
10 μ l are added without RNase water, dissolve, spectrophotometer is quantitative.
2, reverse transcription: every 25 μ l reverse transcription system includes 100pmol random primer, 2 μ g total serum IgEs, 1 μ of M-MLV reverse transcriptase
0.625 1.25 μ l, 5 × M-MLV buffer of μ l, dNTPs (10mM) of l, RNase inhibitor, 5 μ l, remaining uses ddH2O polishing is to 25 μ
l.Reaction condition are as follows: 37 DEG C of 1h, 95 DEG C of 5min.
3, quantitative PCR: every 20 μ l reaction system includes 2 × PCR Mix (ABI) 10 μ l, each 0.4 μ l of upstream and downstream primer,
CDNA1 μ l, ddH2O 8.2μl.Reaction condition are as follows: 94 DEG C of 2min, 94 DEG C of 15s, 60 DEG C of 40s, 40 circulations.It is used in experiment
To primer sequence be shown in Table 1.
1 fluorescence quantitative RT-PCR primer sequence of table
Fig. 1 shows differential expression of the ROGDI in normal cell and breast cancer cell.Wherein, MCF-10A (is abbreviated as
It 10A) is normal cell, MCF7, MDA-MB-231 (being abbreviated as 231), BT-474 and SK-BR-3 are breast cancer cell.Such as Fig. 1 institute
Show, RT-qPCR as the result is shown: the ROGDI gene expression in MCF7, MDA-MB-231, BT-474 and SK-BR-3 breast cancer cell
(P < 0.01, P < 0.01, P < 0.05, P < 0.05) is significantly increased compared with control group MCF-10A cell.
Embodiment 2
The present embodiment is for illustrating that striking low ROGDI gene expression can inhibit breast cancer to be proliferated and/or grow.
One, the preparation of RNAi slow virus clone
1, shot design
3 RNAi target sequences, ROGDI gene are designed according to RNAi sequence design principle for ROGDI gene order
3 kinds of siRNA nucleotide sequence and negative control (NC) nucleotide sequence.3 kinds of siRNA and negative control are corresponding
Title be respectively ROGDI-si-1a, ROGDI-si-1b, ROGDI-si-2a, ROGDI-si-2b, ROGDI-si-3a,
ROGDI-si-3b, NC-si-a and NC-si-b are the sequence designed for negative control group.See Table 2 for details.
The nucleotide sequence of table 23 RNA disturbance target points (siRNA) and negative control
Table 3 shows the nucleotide sequence of 3 kinds of shRNA used in embodiment, shRNA used in embodiment be ROGDI-sh-1a,
The nucleotide sequence of ROGDI-sh-1b, ROGDI-sh-2a, ROGDI-sh-2b, ROGDI-sh-3a, ROGDI-sh-3b, NC-
Sh-a and NC-sh-b is the nucleotide sequence of control group.See Table 3 for details.
The nucleotide sequence of table 33 kinds of shRNA and negative control
Table 4 shows the nucleotide sequence of the DNA of code used 3 kinds of shRNA.The DNA of the code used shRNA of embodiment is
The nucleotides sequence of ROGDI-d-1a, ROGDI-d-1b, ROGDI-d-2a, ROGDI-d-2b, ROGDI-d-3a, ROGDI-d-3b
Column, NC-d-a and NC-d-b are the nucleotide sequence of control group.See Table 4 for details.
The DNA of 43 kinds of shRNA of table and the nucleotide sequence of negative control
2, carrier digestion
50 μ l digestion systems are prepared according to table 5.Various reagents are sequentially added by tab sequential, are gently blown and beaten with pipettor mixed
Even, brief centrifugation is placed in 37 DEG C of reaction 3h.Agarose gel electrophoresis is carried out to carrier digestion products, recycles purpose band.
5 carrier digestion system of table
3, the DNA of shRNA anneals to form double-stranded DNA
The DNA dry powder of pairs of shRNA is dissolved in annealing buffer after synthesis, and 90 DEG C of water-bath 15min are naturally cooled to
Room temperature.
4, carrier connects
The carrier that double digestion linearizes is connected with annealing double-stranded DNA by T4 DNA ligase (T4 DNA ligase),
16 DEG C of connection 1-3h.
6 carrier linked system of table
| Reagent | Volume (μ l) |
| Linearized vector (100ng/ μ l) | 1 |
| Double-stranded DNA (100ng/ μ l) | 1 |
| 10 × T4 DNA ligase buffer | 2 |
| T4 DNA ligase | 1 |
| Distilled water (ddH2O) | Complement to 20 |
5, it converts
10 μ L connection reaction products are added in 100 μ L competent cells, flicks and is mixed under tube wall number, placed on ice
30min；42 DEG C of heat shock 90s, ice bath are incubated for 2min；500 μ L LB culture mediums are added, are placed in 37 DEG C of shaking table shaken cultivation 1h；It takes suitable
Amount bacterium solution is uniformly coated on the plate containing corresponding antibiotic, and culture 12-16h is inverted in constant incubator.
6, sequencing identification
The positive colony transformant identified is inoculated in the LB liquid medium containing corresponding antibiotic in right amount, 37 DEG C of trainings
12-16h is supported, appropriate bacterium solution is taken to be sequenced, identified.
7, plasmid transfection and slow virus harvest
Virus packaging is related to three plasmids altogether: carrying the tool carrier plasmid GV493 carrier of target sequence (purchased from Shang Haiji
Triumphant Gene Tech. Company Limited), virus packaging 1.0 carrier of helper plasmid Helper is (purchased from the lucky triumphant limited public affairs of Gene science in Shanghai
Department) and virus packaging 2.0 carrier of helper plasmid Helper (being purchased from Shanghai Ji Kai Gene Tech. Company Limited).Using above-mentioned three
A plasmid co-transfection 293T cell.
Before transfection for 24 hours, it with the 293T cell of trypsin digestion logarithmic growth phase, is adjusted with the culture medium containing 10% serum
Cell density about 5 × 106/ 15ml is reinoculated on 10cm Tissue Culture Dish, 37 DEG C, 5%CO2Culture in incubator；For 24 hours to thin
It can be used to transfect when born of the same parents' density is up to 70%~80%；2h is changed to serum free medium before transfecting；Sterile centrifugation tube is taken, is added
Each DNA solution (20 μ g of GV493 plasmid, 1.0 pHelper vector plasmid, 15 μ g, 2.0 pHelper vector plasmid, 10 μ g), with phase
The triumphant transfection reagent of Ji of volume is answered to be uniformly mixed, adjustment total volume is 1ml, incubates 15min at room temperature；Mixed liquor is slowly added dropwise
Into 293T cell culture fluid, mix, in 37 DEG C, 5%CO2It is cultivated in cell incubator；It is discarded after culture 6h mixed containing transfection
With the culture medium of object, the PBS cleaning that 10ml is added is primary, falls after the soft transfection mixture for shaking culture dish to wash remnants
It abandons.
It is slowly added to the cell culture medium 20ml containing 10% serum, in 37 DEG C, 5%CO2Continue to cultivate 48- in incubator
72h。
8, slow virus concentration and purifying and quality inspection
According to cell state, the 293T cell supernatant of 48h (transfection can be calculated as 0h) after transfection is collected；In 4 DEG C,
4000g is centrifuged 10min, removes cell fragment；With 0.45 μm of filter filtering supernatant in 40ml ultracentrifugation pipe；Trim respectively
Ultracentrifugation pipe with vial supernatant is put into Beckman ultracentrifuge, 4 DEG C, 25000rpm by sample one by one,
It is centrifuged 2h；It after centrifugation, discards supernatant, removal as far as possible remains in the liquid on tube wall, and virus is added and saves liquid, gently repeatedly
Piping and druming is resuspended；Through after completely dissolution, after high speed centrifugation 10000rpm, 5min, supernatant being taken to dispense as required.
The key Quality Control of slow virus includes physical state detection, Sterility testing and virus titer detection.
Two, slow-virus transfection
To guarantee that gene jamming effectiveness, the present embodiment design 3 kinds of RNA disturbance target points (siRNA) for ROGDI gene, and
3 plasmid equal proportions for carrying different target spots are mixed and carry out slow virus packaging, so that it is guaranteed that purpose base after virus infected cell
Cause strikes reduction rate.
Cell secondary culture is into 6 orifice plates after 12-16 hours: virus liquid 0.15ml and fresh cell medium mixed,
Ratio is that 0.5ml fresh medium and 0.65 μ l polybrene (final concentration 4ng/ml) are added in 0.15ml vial supernatant；
Pre- mixed virus infection liquid is added in aim cell culture dish, and cell density is no more than 50% at this time.After being incubated overnight
It is replaced with fresh medium.
After infection 3 days, logarithmic growth phase cell carries out cell proliferation experiment.
Three, cell proliferation experiment
Above-mentioned control group and the cell in logarithmic growth phase for striking low ROGDI expression are subjected to pancreatin digestion, are made thin
Born of the same parents' suspension；Cell suspension (cell number is about 3000) is inoculated in 96 orifice plates, is counted respectively at the 1st day, 2 days, 3 days, 4 days, 5 days
Cell quantity is calculated, growth curve is drawn.
Fig. 2 shows strike influence of the low ROGDI to Cells Proliferation of Human Breast Cancer.Wherein, shCtrl is control group, shROGDI
For experimental group, the curve of top is control group, and the curve of lower section is experimental group.As shown in Fig. 2, cell proliferation experiment result is aobvious
Show, strike the expression of low ROGDI gene, significantly inhibited proliferation (P < 0.001, the P of breast cancer cell MCF7 with the 5th day on day 4
<0.001)。
Four, human breast cancer in nude mice lotus knurl is tested
Cell suspension is respectively prepared in control group and the MCF7 breast cancer cell line for striking low ROGDI, carries out nude mice by subcutaneous kind
It plants.Every group of 6 mouse, every mouse inoculation 100 μ l, 5 × 106A cell.After 1.5 months, tumor size and volume are detected, into
Row statistical analysis.
Fig. 3 shows the influence for striking low ROGDI to tumor-bearing mice growth of breast cancers.Wherein, NC is control group, shROGDI
For experimental group.As shown in figure 3, mouse-borne tumor experimental result is shown, ROGDI low expression group Breast Cancer tumor volume is substantially less than pair
According to group (P < 0.01).As it can be seen that breast cancer cell growth can be significantly inhibited by reducing the expression of ROGDI gene.
Various embodiments of the present invention are described above, above description is exemplary, and non-exclusive, and
It is not limited to disclosed each embodiment.Without departing from the scope and spirit of illustrated each embodiment, for this skill
Many modifications and changes are obvious for the those of ordinary skill in art field.
Sequence table
<110>Jiangsu medical profession institute
<120>siRNA, recombinant vector and its application of ROGDI gene expression are reduced
<141> 2019-03-18
<160> 28
<170> SIPOSequenceListing 1.0
<210> 2
<211> 21
<212> RNA
<213> Artificial Sequence
<400> 2
gcuggucaac gucuacauca a 21
<210> 3
<211> 21
<212> RNA
<213> Artificial Sequence
<400> 3
uugauguaga cguugaccag c 21
<210> 3
<211> 21
<212> RNA
<213> Artificial Sequence
<400> 3
ccaugugagc caagccauuu a 21
<210> 4
<211> 21
<212> RNA
<213> Artificial Sequence
<400> 4
uaaauggcuu ggcucacaug g 21
<210> 5
<211> 21
<212> RNA
<213> Artificial Sequence
<400> 5
cccaccuaac acauuugcac u 21
<210> 6
<211> 21
<212> RNA
<213> Artificial Sequence
<400> 6
agugcaaaug uguuaggugg g 21
<210> 7
<211> 19
<212> RNA
<213> Artificial Sequence
<400> 7
uucuccgaac gugucacgu 19
<210> 8
<211> 19
<212> RNA
<213> Artificial Sequence
<400> 8
acgugacacg uucggagaa 19
<210> 9
<211> 58
<212> RNA
<213> Artificial Sequence
<400> 9
ccgggcuggu caacgucuac aucaacucga guugauguag acguugacca gcuuuuug 58
<210> 10
<211> 58
<212> RNA
<213> Artificial Sequence
<400> 10
aauucaaaaa gcuggucaac gucuacauca acucgaguug auguagacgu ugaccagc 58
<210> 11
<211> 58
<212> RNA
<213> Artificial Sequence
<400> 11
ccggccaugu gagccaagcc auuuacucga guaaauggcu uggcucacau gguuuuug 58
<210> 12
<211> 58
<212> RNA
<213> Artificial Sequence
<400> 12
aauucaaaaa ccaugugagc caagccauuu acucgaguaa auggcuuggc ucacaugg 58
<210> 13
<211> 58
<212> RNA
<213> Artificial Sequence
<400> 13
ccggcccacc uaacacauuu gcacucucga gagugcaaau guguuaggug gguuuuug 58
<210> 14
<211> 58
<212> RNA
<213> Artificial Sequence
<400> 14
aauucaaaaa cccaccuaac acauuugcac ucucgagagu gcaaaugugu uagguggg 58
<210> 15
<211> 57
<212> RNA
<213> Artificial Sequence
<400> 15
ccgguucucc gaacguguca cguuucaaga gaacgugaca cguucggaga auuuuug 57
<210> 16
<211> 57
<212> RNA
<213> Artificial Sequence
<400> 16
aauucaaaaa uucuccgaac gugucacguu cucuugaaac gugacacguu cggagaa 57
<210> 17
<211> 58
<212> DNA
<213> Artificial Sequence
<400> 17
ccgggctggt caacgtctac atcaactcga gttgatgtag acgttgacca gctttttg 58
<210> 18
<211> 58
<212> DNA
<213> Artificial Sequence
<400> 18
aattcaaaaa gctggtcaac gtctacatca actcgagttg atgtagacgt tgaccagc 58
<210> 19
<211> 58
<212> DNA
<213> Artificial Sequence
<400> 19
ccggccatgt gagccaagcc atttactcga gtaaatggct tggctcacat ggtttttg 58
<210> 20
<211> 58
<212> DNA
<213> Artificial Sequence
<400> 20
aattcaaaaa ccatgtgagc caagccattt actcgagtaa atggcttggc tcacatgg 58
<210> 21
<211> 58
<212> DNA
<213> Artificial Sequence
<400> 21
ccggcccacc taacacattt gcactctcga gagtgcaaat gtgttaggtg ggtttttg 58
<210> 22
<211> 58
<212> DNA
<213> Artificial Sequence
<400> 22
aattcaaaaa cccacctaac acatttgcac tctcgagagt gcaaatgtgt taggtggg 58
<210> 23
<211> 57
<212> DNA
<213> Artificial Sequence
<400> 23
ccggttctcc gaacgtgtca cgtttcaaga gaacgtgaca cgttcggaga atttttg 57
<210> 24
<211> 57
<212> DNA
<213> Artificial Sequence
<400> 24
aattcaaaaa ttctccgaac gtgtcacgtt ctcttgaaac gtgacacgtt cggagaa 57
<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 25
tgtggcacag accaggtgaa 20
<210> 26
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 26
aggtaaatgg cttggctcac a 21
<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 27
ggcacccagc acaatgaaga 20
<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 28
actcctgctt gctgatccac 20
Claims (10)
1. a kind of siRNA, which is characterized in that the siRNA specifically reduces ROGDI gene expression.
2. siRNA according to claim 1, which is characterized in that the nucleotide sequence of the siRNA is included at least with next
Group nucleotide sequence:
(1) first group of nucleotide sequence
For first group of nucleotide sequence as shown in SEQ ID NO:1 and SEQ ID NO:2, the SEQ ID NO:1 is 5'-
GCUGGUCAACGUCUACAUCAA-3', the SEQ ID NO:2 are 5'-UUGAUGUAGACGUUGACCAGC-3'；
(2) second groups of nucleotide sequences
For second group of nucleotide sequence as shown in SEQ ID NO:3 and SEQ ID NO:4, the SEQ ID NO:3 is 5'-
CCAUGUGAGCCAAGCCAUUUA-3', the SEQ ID NO:4 are 5'-UAAAUGGCUUGGCUCACAUGG-3'；
(3) third group nucleotide sequence
For the third group nucleotide sequence as shown in SEQ ID NO:5 and SEQ ID NO:6, the SEQ ID NO:5 is 5'-
CCCACCUAACACAUUUGCACU-3', the SEQ ID NO:6 are 5'-AGUGCAAAUGUGUUAGGUGGG-3'.
3. a kind of shRNA, which is characterized in that the nucleotide sequence of the shRNA includes at least following set of nucleotide sequence:
(1) the 5th group of nucleotide sequence
For the 5th group of nucleotide sequence as shown in SEQ ID NO:9 and SEQ ID NO:10, the SEQ ID NO:9 is 5'-
CCGGGCUGGUCAACGUCUACAUCAACUCGAGUUGAUGUAGACGUUGACCAGCUUUU UG-3', the SEQ ID NO:
10 be 5'-AAUUCAAAAAGCUGGUCAACGUCUACAUCAACUCGAGUUGAUGUAGACGUUGA CCAGC-3'；
(2) the 6th groups of nucleotide sequences
As shown in SEQ ID NO:11 and SEQ ID NO:12, the SEQ ID NO:11 is the 6th group of nucleotide sequence
5'-CCGGCCAUGUGAGCCAAGCCAUUUACUCGAGUAAAUGGCUUGGCUCACAUGGU UUUUG-3', the SEQ ID
NO:12 is 5'-AAUUCAAAAACCAUGUGAGCCAAGCCAUUUACUCGAGUAAAUGGCUUGGCUCA CAUGG-3'；
(3) the 7th groups of nucleotide sequences
As shown in SEQ ID NO:13 and SEQ ID NO:14, the SEQ ID NO:13 is the 7th group of nucleotide sequence
5'-CCGGCCCACCUAACACAUUUGCACUCUCGAGAGUGCAAAUGUGUUAGGUGGGU UUUUG-3', the SEQ ID
NO:14 is 5'-AAUUCAAAAACCCACCUAACACAUUUGCACUCUCGAGAGUGCAAAUGUGUUAG GUGGG-3'.
4. encoding the DNA of shRNA as claimed in claim 3, which is characterized in that the nucleotide sequence of the DNA include at least with
Next group of nucleotide sequence:
(1) the 9th group of nucleotide sequence
As shown in SEQ ID NO:17 and SEQ ID NO:18, the SEQ ID NO:17 is the 9th group of nucleotide sequence
5'-CCGGGCTGGTCAACGTCTACATCAACTCGAGTTGATGTAGACGTTGACCAGCT TTTTG-3', the SEQ ID
NO:18 is 5'-AATTCAAAAAGCTGGTCAACGTCTACATCAACTCGAGTTGATGTAGACGTTGA CCAGC-3'；
(2) the tenth groups of nucleotide sequences
As shown in SEQ ID NO:19 and SEQ ID NO:20, the SEQ ID NO:19 is described ten group of nucleotide sequence
5'-CCGGCCATGTGAGCCAAGCCATTTACTCGAGTAAATGGCTTGGCTCACATGGT TTTTG-3', the SEQ ID
NO:20 is 5'-AATTCAAAAACCATGTGAGCCAAGCCATTTACTCGAGTAAATGGCTTGGCTCA CATGG-3'；
(3) the 11st groups of nucleotide sequences
As shown in SEQ ID NO:21 and SEQ ID NO:22, the SEQ ID NO:21 is the 11st group of nucleotide sequence
5'-CCGGCCCACCTAACACATTTGCACTCTCGAGAGTGCAAATGTGTTAGGTGGGT TTTTG-3', the SEQ ID
NO:22 is 5'-AATTCAAAAACCCACCTAACACATTTGCACTCTCGAGAGTGCAAATGTGTTAG GTGGG-3'.
5. a kind of recombinant vector, which is characterized in that the recombinant vector be GV493 plasmid multiple cloning sites AgeI and
EcoRI insertion such as encodes the recombinant vector that the DNA of coding shRNA as claimed in claim 4 is obtained.
6. a kind of recombinant slow virus, which is characterized in that recombinant slow virus recombinant vector as described in claim 5 and virus
It packs 1.0 carrier of helper plasmid pHelper and virus packaging 2.0 carrier cotransfection mammal of helper plasmid pHelper is thin
Born of the same parents obtain.
7. a kind of host cell, which is characterized in that including siRNA of any of claims 1 or 2, as claimed in claim 3
ShRNA, the coding DNA of shRNA as claimed in claim 4, recombinant vector described in claim 5 and as claimed in claim 6
At least one of recombinant slow virus.
8. siRNA of any of claims 1 or 2, shRNA as claimed in claim 3, coding shRNA's as claimed in claim 4
At least one of recombinant vector described in DNA, claim 5 and recombinant slow virus as claimed in claim 6 inhibit in preparation
Application in the preparation of ROGDI gene expression.
9. siRNA of any of claims 1 or 2, shRNA as claimed in claim 3, coding shRNA's as claimed in claim 4
At least one of recombinant vector described in DNA, claim 5 and recombinant slow virus as claimed in claim 6 inhibit in preparation
Application in breast cancer cell growth and/or the drug of proliferation.
10. siRNA of any of claims 1 or 2, shRNA as claimed in claim 3, coding shRNA as claimed in claim 4
DNA, at least one of recombinant vector and recombinant slow virus as claimed in claim 6 are controlled in preparation described in claim 5
Application in the drug for the treatment of and/or prevention breast cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910203977.6A CN110042101B (en) | 2019-03-18 | 2019-03-18 | siRNA for reducing ROGDI gene expression, recombinant vector and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910203977.6A CN110042101B (en) | 2019-03-18 | 2019-03-18 | siRNA for reducing ROGDI gene expression, recombinant vector and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110042101A true CN110042101A (en) | 2019-07-23 |
| CN110042101B CN110042101B (en) | 2021-10-15 |
Family
ID=67273824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910203977.6A Active CN110042101B (en) | 2019-03-18 | 2019-03-18 | siRNA for reducing ROGDI gene expression, recombinant vector and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110042101B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101433724A (en) * | 2007-11-16 | 2009-05-20 | 天津医科大学附属肿瘤医院 | Use of Akt2-siRNA fusion expression vector in preparing medicament for inhibiting metastasis of human breast cancer cell |
| CN108949827A (en) * | 2018-07-20 | 2018-12-07 | 深圳市南山区疾病预防控制中心 | The special shRNA Lentiviral for inhibiting lung cancer PPARd gene expression and its construction method and application |
-
2019
- 2019-03-18 CN CN201910203977.6A patent/CN110042101B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101433724A (en) * | 2007-11-16 | 2009-05-20 | 天津医科大学附属肿瘤医院 | Use of Akt2-siRNA fusion expression vector in preparing medicament for inhibiting metastasis of human breast cancer cell |
| CN108949827A (en) * | 2018-07-20 | 2018-12-07 | 深圳市南山区疾病预防控制中心 | The special shRNA Lentiviral for inhibiting lung cancer PPARd gene expression and its construction method and application |
Non-Patent Citations (3)
| Title |
|---|
| YI-FAN CHEN等: "Downregulation of a novel human gene,ROGDI,increases radiosensitivity in cervical cancer cells", 《CANCER BIOLOGY AND THERAPY》 * |
| 刘林林: "《恶性肿瘤生物治疗学》", 30 November 2013, 人民军医出版社 * |
| 刘静: "《分子生物学实验指导》", 31 December 2015, 中南大学出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110042101B (en) | 2021-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105524924B (en) | Cyclic RNA circ-ZKSCAN1 use | |
| CN106191067B (en) | Circular rna circ-NFATC3 and application thereof | |
| CN104651509B (en) | Osteosarcomatous medicine new target drone | |
| CN106834290B (en) | Circular RNA and application thereof | |
| CN107663539B (en) | Use of circular RNA circ-PTGR1 | |
| CN110123828A (en) | Application of the inhibitor of PRALR in the drug that resistance to taxol oophoroma is treated in preparation | |
| CN104611449B (en) | Application of the WWP1 genes in osteosarcoma diagnostic products and medicine is prepared | |
| CN104774966B (en) | Adenocarcinoma of lung miRNA labels | |
| CN110042101A (en) | Reduce siRNA, recombinant vector and its application of ROGDI gene expression | |
| CN110055249A (en) | Reduce siRNA, recombinant vector and its application of THEM6 gene expression | |
| CN110117593A (en) | Specificity reduces the application of the nucleic acid, recombinant vector and recombinant slow virus of FAM84B gene expression | |
| CN109988762A (en) | Reduce siRNA, recombinant vector and its application of PSMD12 gene expression | |
| CN110129321A (en) | siRNA for reducing LSG1 gene expression, recombinant vector and application thereof | |
| CN109988764A (en) | Reduce siRNA, recombinant vector and its application of NKIRAS2 gene expression | |
| CN110079527A (en) | Reduce siRNA, recombinant vector and its application of OSBPL2 gene expression | |
| CN105462928B (en) | A kind of Chinese oral cavity K-1735 COMM-1 and its method for building up | |
| CN110129319A (en) | A kind of siRNA of PRALR and application thereof | |
| CN110144348A (en) | SiRNA, recombinant vector and its application expressed for striking low DEAH box unwindase 16 | |
| CN104630221B (en) | Suppress shRNA and its recombinant vector and the application of growth of tumour cell | |
| CN104774872B (en) | Change the method and its application of cell fate | |
| CN107267636A (en) | LncRNA GENE NO.9 application and the diagnosticum and healing potion of carcinoma of urinary bladder | |
| CN104774928B (en) | The application of people's RRS1 genes and inhibitor | |
| CN103667431B (en) | A kind of purposes and its related drugs of people CCCH types zinc finger protein expressing gene | |
| CN114181936B (en) | shRNA for inhibiting chicken CA13 gene expression and application thereof | |
| CN108624689A (en) | The application of biomarker LINC01451 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211230 Address after: Room 01, building 13, No.1, Zhaoyan Road, Shaxi Town, Taicang City, Jiangsu Province Patentee after: Qianyuan Kangan (Suzhou) Biotechnology Co.,Ltd. Address before: 2081, building a, 88 Jianghai West Road, Liangxi District, Wuxi City, Jiangsu Province, 214000 Patentee before: Wuxi Xiangyuan Information Technology Co.,Ltd. Effective date of registration: 20211230 Address after: 2081, building a, 88 Jianghai West Road, Liangxi District, Wuxi City, Jiangsu Province, 214000 Patentee after: Wuxi Xiangyuan Information Technology Co.,Ltd. Address before: 224008 no.283, Jiefang South Road, Yancheng City, Jiangsu Province Patentee before: JIANGSU VOCATIONAL College OF MEDICINE |
|
| TR01 | Transfer of patent right |